Volition Update

RNS Number : 7334P

ValiRx PLC

07 October 2011

 



ValiRx Plc

("ValiRx" or the "Company")

Volition Update

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, notes that Singapore Volition Pte. Limited ("Volition") has today announced the closure of its share exchange agreement with Standard Capital Corporation, a Delaware corporation currently quoted on the OTC Bulletin Board under the symbol SNDC.OB. Accordingly, ValiRx refers shareholders to the Company's update on Volition dated 27 September 2011.

- ENDS -

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.ValiRx.com
Cairn Financial Advisers LLP Nominated Adviser	Tel:[phone]
Liam Murray / Avi Robinson
Hybridan LLP Broker	Tel: [phone]
Claire Noyce
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

·       ValiMedix is the sales and distribution division of ValiRx

·       ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, ValiRx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments

 

END

 

 

MSCEQLFBFBFZFBB